Patents Assigned to Eli Lilly & Company
  • Combinatorial process for preparing substituted thiophene libraries
    Patent number: 5942387
    Abstract: This invention relates to a novel solid phase process for the preparation of thiophene combinatorial libraries. These libraries have use for drug discovery and are used to form wellplate components of novel assay kits.
    Type: Grant
    Filed: August 25, 1997
    Date of Patent: August 24, 1999
    Assignee: Eli Lilly and Company
    Inventor: Sean Patrick Hollinshead
  • Method of treating insulin resistance
    Patent number: 5939387
    Abstract: The present invention is in the field of human medicine, particularly in the treatment of Non-insulin Dependent Diabetes Mellitus (NIDDM) and other insulin resistant states such as those associated with obesity and aging. The invention provides a method of treating insulin resistant mammals, which comprises administering to a mammal in need thereof a growth hormone releasing agent.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Carol Lynn Broderick, Richard Dennis DiMarchi, Mark Louis Heiman, Lawrence Edward Stramm
  • Selective .beta.3 adrenergic agonists
    Patent number: 5939443
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Donald Paul Matthews, John Hampton McDonald, III, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Multiple dose medication dispensing device
    Patent number: 5938642
    Abstract: A multi-use pen-shaped medication dispensing device made of a plastic material that is recyclable after the contents of the medication cartridge have been exhausted. The device is made of a minimal number of parts, which include a housing, a dial assembly, a generally cylindrical button assembly located within the proximal end of the dial assembly, an internally threaded nut, and an externally threaded leadscrew. The device is arranged so that the dial must be rotated to the zero dose position prior to setting a dose. The device includes a lockout mechanism that prevents the dial from being depressed during dosing. The device further includes a mechanism that limits the maximum dosage that can be dialed up and a mechanism that prevents the user from dialing up a dosage greater than that remaining in the cartridge.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Andrew Burroughs, Dave Hixson, Andrew Hodge
  • Reducing agent for reductive alkylation of glycopeptide antibiotics
    Patent number: 5939382
    Abstract: This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics, the improvement residing in employing pyridine.borane as reducing agent.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Richard Alan Berglund, Hua Zheng
  • Process for environmentally safe cleaning using water-soluble polymer based packages
    Patent number: 5935366
    Abstract: A process for preparing two connected powder transfer conduits for cleaning without releasing powder from the conduits. The conduits are connected to each other by flexible tube of a water-dissolvable material to enable powder communication between the two conduits. A sealing operation is performed to form a seal in the tube sufficient to prevent the powder communication from one side of the seal to the other. The seal is then severed to produce two tube sections where each tube section is sealed at the point of severance. A cleaning conduit is then place over at least one of the two tube sections and connected to the respective conduit. The cleaning conduit is connected to a liquid cleaning source which is adapted to deliver a cleaning liquid capable of dissolving the tube section thereunder upon contact therewith.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: August 10, 1999
    Assignee: Eli Lilly and Company
    Inventor: James P. Wood
  • Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta?6,!benzofurans
    Patent number: 5935992
    Abstract: The invention provides substituted-2-amino-1,2,3,4-tetrahydrodibenzofurans and 2-aminocyclohepta?b!benzo-furans useful as 5-HT.sub.1F agonists.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: August 10, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael E. Flaugh, Anton D. Kiefer, Jr.
  • Modified platelet factor-4
    Patent number: 5935928
    Abstract: The present invention is based of the discovery of two modified forms of human platelet factor-4, herein named MPF-4 and CPF-4, which were isolated from serum free culture medium of lipopolysaccharide-stimulated peripheral blood leukocytes. Amino acid sequence determination revealed that MPF-4 shares homology with platelet factor-4 beginning at N-terminal residue 17. CPF-4 consists of MPF-4 disulfide bonded to the 16 N-terminal residues of platelet factor-4. Both MPF-4 and CPF-4 are potent inhibitors of endothelial cell proliferation, approximately 10-100 fold more potent than native or recombinant platelet factor-4, making them useful in the treatment of angiogenic diseases.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: August 10, 1999
    Assignee: Eli Lilly and Company
    Inventors: Shalley K. Gupta, Jai Pal Singh
  • Teicoplanin deacylation process and product
    Patent number: 5936074
    Abstract: The present invention is directed to deacyl teicoplanin, and to a process for preparing deacyl teicoplanin by reacting teicoplanin with ECB deacylase. Deacyl teicoplanin can be alkylated to produce compounds useful for their antibacterial activity.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: August 10, 1999
    Assignee: Eli Lilly and Company
    Inventors: Barbara Shreve Briggs, Robin David Grey Cooper, Adam Joseph Kreuzman, Milton Joseph Zmijewski, Jr.
  • Halo-substituted bisindolemaleimide protein kinase C inhibitors
    Patent number: 5936084
    Abstract: The present invention is directed to novel halo-substituted bis-indolemaleimide compounds of the formula: ##STR1## The invention further provides a method of preparing the disclosed compounds and the preparation of pharmaceutical formulation for use in inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: August 10, 1999
    Assignees: Eli Lilly and Company, Mississippi State University
    Inventors: Michael R. Jirousek, Peter G. Goekjian, Guo-Zhang Wu
  • Glucosltransferase gene GTFE from amycolatopsis orientalis
    Patent number: 5932464
    Abstract: The invention provides isolated nucleic acid compounds encoding a glycosyltransferase enzyme of Amycolatopsis orientalis. Also provided are vectors carrying genes that encode the enzyme, transformed heterologous host cells for expressing the enzyme, and methods for producing glycopeptide compounds using the cloned genes that encode the enzyme.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: August 3, 1999
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Patricia J. Solenberg, Patti J. Treadway
  • Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta?6,!benzofurans
    Patent number: 5932739
    Abstract: The invention provides substituted-2-amino-1,2,3,4-tetrahydrodibenzofurans and 2-aminocyclohepta?b!benzo-furans useful as 5-HT.sub.1F agonists.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: August 3, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael E. Flaugh, Anton D. Kiefer, Jr.
  • Cyclic peptide antifungal agents and process for preparation thereof
    Patent number: 5932543
    Abstract: Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --;R" and R'" are independently methyl or hydrogen;R and R.sup.Y are independently hydroxy or hydrogen;R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy;R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy;R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: August 3, 1999
    Assignee: Eli Lilly and Company
    Inventors: Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
  • Method for treating migraine pain with olanzapine
    Patent number: 5929070
    Abstract: The present invention provides a method for treating migraine pain comprising administering an analgesic dosage of olanzapine.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: Harlan E. Shannon, Daniel E. Womer
  • Lipophilic benzothiophenes for treating estrogen deficiency
    Patent number: 5929092
    Abstract: The invention provides novel benzothiophenes of the formula (I): ##STR1## wherein R.sub.1 is N-pyrrolidinyl or N-piperidinyl;R.sub.2 and R.sub.3 are independently hydrogen, --CO--(C.sub.10 -C.sub.22 alkyl), --CO--(C.sub.10 -C.sub.22 branched alkyl), --CO--(C.sub.10 -C.sub.22 alkenyl), --CO--(C.sub.10 -C.sub.22 polyalkenyl), --CO--(C.sub.10 -C.sub.22 alkynyl), or --CO--(CH.sub.2).sub.n COR.sub.4 ; provided R.sub.2 and R.sub.3 are not both dodecanoyl, and one of R.sub.2 or R.sub.3 is not hydrogenR.sub.4 is -3-cholesteryl or --O(CH.sub.2).sub.2 (OR.sub.5)CH.sub.2 OR.sub.6 ;R.sub.5 and R.sub.6 are independently hydrogen, --CO--(C.sub.10 -C.sub.22 alkyl), --CO--(C.sub.10 -C.sub.22 branched alkyl), --CO--(C.sub.10 -C.sub.22 alkenyl), --CO--(C.sub.10 -C.sub.22 polyalkenyl), or --CO--(C.sub.10 -C.sub.22 alkynyl); provided one of R.sub.5 or R.sub.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Raymond Francis Kauffman
  • Heterocyclic compounds and their preparation and use
    Patent number: 5929247
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • 1H-2,1,3-benzothiadiazine-2,2-dioxide compounds or derivatives thereof
    Patent number: 5929072
    Abstract: A pharmaceutical compound having the formula: ##STR1## in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3,R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-4 alkyl,R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkyl, or R.sup.3 and R.sup.4 together form an alkylene link of formula --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 --, or R.sup.4 and R.sup.5 together with the carbon atom to which they are attached form a C.sub.3-6 cycloalkyl group,R.sup.6 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino,the dotted line represents an optional double bond, andthe fluorine atom is attached at the 6 or 7-position;and salts and esters thereof.
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company Limited
    Inventor: John Fairhurst
  • Multiple drug resistance gene atrD of Aspergillus nidulans
    Patent number: 5928898
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus nidulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus nidulans atrD are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: Paul Luther Skatrud, Maarten A. de Waard, Alan C. Andrade, Robert Brown Peery
  • 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
    Patent number: 5929090
    Abstract: The present invention provides a compound of formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof; having activity as a selective estrogen receptor modulator, pharmaceutical compositions containing a compound of formula I, and methods of using a compound of formula I for treating conditions resulting from estrogen deprivation or the inappropriately high presence of estrogen. Also provided are methods and chemical intermediates for the production of a compound of formula I above.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Alan David Palkowitz
  • Synthetic excitatory amino acids
    Patent number: 5925680
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: July 20, 1999
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, James A. Monn, Darryle D. Schoepp, Joseph P. Tizzano